Takeda Pharmaceutical Company

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Global $70 Billion Regenerative Medicine Market Analysis to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023

The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region" report has been added to ResearchAndMarkets.com's offering.
  • The Global Regenerative Medicine Market - which grew from approximately US$ 15 billion in 2017 to approximately US$ 30 billion in 2022 - is forecasted to grow further into approximately US$ 70 billion opportunities by 2028, owing to the growing severe diseases, infections, and cancers.
  • Regenerative medicine market is driven by surging trauma cases, genetic disorders, chronic diseases, and other infectious viruses.
  • The rising number of cancer patients worldwide is driving the growth of the regenerative medicine market.

Fujitsu conducts project with Takeda and National Cancer Center Japan to analyze and visualize of patient journey with ovarian cancer

Retrieved on: 
Friday, May 12, 2023

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.

Key Points: 
  • These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.
  • This study was conducted based on a joint research agreement that Fujitsu concluded with Takeda and the National Cancer Center Japan in May 2021 with the aim of identifying clinical challenges that will contribute to improving the quality and therapeutic efficacy of personalized ovarian cancer treatment.
  • In the future, the platform will be able to extract patient medical data and convert it into HL7 FHIR(2).
  • It includes electronic medical record data, medical accounting data, health checkup data, patient registry data, and data obtained from wearable devices.

BioLife Solutions Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023

BOTHELL, Wash., May 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2023.

Key Points: 
  • BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP).
  • Gross margin (GAAP) for the first quarter of 2023 was 35% compared with 28% for the first quarter of 2022.
  • Operating expense (GAAP) for the first quarter of 2023 was $51.3 million compared with $44.2 million for the first quarter of 2022.
  • Adjusted operating expense (non-GAAP) for the first quarter of 2023 was $25.5 million compared with $20.1 million for the first quarter 2022.

Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

Retrieved on: 
Friday, May 5, 2023

EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.

Key Points: 
  • EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab).
  • The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.
  • In the race to capture second-line UC patients, Janssen's Stelara (approved for UC in 2019) is currently favored by physicians.
  • Spherix will be monitoring the potential Entyvio SC US launch and the evolving UC market through its RealTime Dynamix™ advisory service.

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, April 27, 2023

Ovid maintains a significant financial interest in soticlestat, including potential milestones payments and royalties, if soticlestat receives regulatory approval and is commercialized.

Key Points: 
  • Ovid maintains a significant financial interest in soticlestat, including potential milestones payments and royalties, if soticlestat receives regulatory approval and is commercialized.
  • The interim analysis of ENDYMION 1 presented at AAN included 47 patients with DS and 83 patients with LGS.
  • Soticlestat demonstrated a sustained reduction in frequency of convulsive (DS) and drop (LGS) seizures from baseline up to 2 years.
  • At the AAN meeting, Takeda additionally presented post-hoc analysis data from the Phase 2 ELEKTRA study, which evaluated the efficacy of treatment with soticlestat by seizure type in patients with DS or LGS.

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

Retrieved on: 
Wednesday, April 26, 2023

WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients. 

Key Points: 
  • WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria.
  • Corza Medical had previously acquired the commercial product rights for TachoSil , a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021.
  • Corza Medical shares Takeda’s commitment to patient care and has the experience and resources to continue investing in TachoSil for the benefit of patients.
  • “We look forward to welcoming the Takeda TachoSil operations team to Corza Medical to support our investment in expanding manufacturing capacity, testing systems, and R&D facilities to develop new Biosurgery offerings,” said Tom Testa, Corza Medical Chief Executive Officer.

ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer

Retrieved on: 
Monday, April 24, 2023

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
  • "We are excited to welcome Isabel to ImmunoGen's Executive Committee to lead our best-in-class commercial organization at this important moment for the company.
  • Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals.
  • "I am delighted to join ImmunoGen during this exciting time in its evolution into a commercial organization," said Ms. Kalofonos.

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

Retrieved on: 
Tuesday, April 18, 2023

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towards addressing the significant unmet medical need for gastric cancer patients.

Key Points: 
  • Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towards addressing the significant unmet medical need for gastric cancer patients.
  • Gastric cancer is one of the most common cancers globally, with the highest incidence and mortality rates found in Asian populations.
  • China alone accounts for over 40% of all new gastric cancer cases in the world.
  • In China, fruquintinib is approved under the brand name ELUNATE® and is included in the China National Reimbursement Drug List (“NRDL”).

Armis Announces Significant Business Momentum in Healthcare

Retrieved on: 
Monday, April 17, 2023

HIMSS – Armis , the leading asset visibility and security company, today announced significant business momentum in the healthcare sector driven by healthcare and life sciences companies choosing the Armis Platform to identify and secure their medical devices.

Key Points: 
  • HIMSS – Armis , the leading asset visibility and security company, today announced significant business momentum in the healthcare sector driven by healthcare and life sciences companies choosing the Armis Platform to identify and secure their medical devices.
  • Over the past year, Armis has continued to grow its partnerships with new customers across the healthcare sector, resulting in 115% customer growth year-over-year, on average.
  • “Our work in the healthcare sector is critically important,” said Yevgeny Dibrov, CEO and Co-founder of Armis.
  • Additionally, Armis was recognized as a Hot Company in Healthcare IoT Security in Cyber Defense Magazine’s Global InfoSec Awards.